DV
Dividend Vision

TLPH — Talphera Inc.

Talphera Inc. (TLPH)

Total return is -98.6% over the past 15.5 years, 765.1 points behind SPY at 666.5%. Its deepest 1-year drawdown was 50.5%.

Talphera, Inc. is a specialty pharmaceutical company developing therapies for use in medically supervised settings, including its lead product candidate Niyad, a regional anticoagulant for use in extracorporeal circuits, and LTX-608, a treatment for conditions including disseminated intravascular coagulation and acute respiratory distress syndrome. The company does not currently distribute dividends. Talphera appeals to investors seeking exposure to clinical-stage pharmaceutical development rather than current income generation.

TLPH key facts

Asset type
Stock
Asset class
Equity
Inception date
02/11/2011
Last close
$1.23
Market cap
$67,988,536
Average volume
341759.0
Beta
0.704
Payout ratio
0.0
Forward P/E
1.0172
EPS
$-0.28